Episode 60: ASM Roundup - Day 3 with Dr. Marinka Twilt and Dr. Mo Osman

A groundbreaking revelation at the 2026 Canadian Rheumatology Association Annual Scientific Meeting exposed a critical blind spot in diagnosing systemic-onset juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease: nearly half of cases are monophasic—meaning patients appear cured after initial treatment, only to relapse years later, often misdiagnosed as new conditions. Dr. Mo Osmond shared that this insight, revealed in a masterclass by Dr. Mike Umbrello, upends long-held assumptions and shifts clinical practice: stopping IL-1 or IL-6 inhibitors may actually improve outcomes in patients with lung complications, and HLA-DRB1*15 is a key biomarker for predicting life-threatening interstitial lung disease. Meanwhile, Dr. Marinka Twilt highlighted stark inequities in pediatric rheumatology care, revealing that Ontario’s biologic drug coverage for JIA far exceeds other provinces—and that even when evidence-based trials exist, patent expirations prevent Health Canada approval, leaving clinicians to treat off-label. The keynote by Dr. Cheryl Barnaby delivered a powerful call to action: true equity requires meeting patients where they are—culturally, geographically, and emotionally—especially for First Nations communities, where systemic bias and mistrust of Western medicine remain profound barriers. Her advocacy during the pandemic, including mobile vaccine clinics, proved that community-based care drives better outcomes than centralized models.